A novel nasal spray formulation of fluticasone propionate and azelastine hydrochloride has been launched in the UK for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis.
The prescription product, branded as Dymista, is licensed for use where monotherapy with either intranasal antihistamine or glucocortocoid is not considered sufficient.
According to trial data presented in March, 17.8% of patients taking Dymista experienced complete or near-to-complete nasal symptom resolution, compared with 9.2% of patients taking fluticasone propionate monotherapy, 8.3% taking azelastine alone and 7.8% of those on a placebo.
The UK license for the treatment has been granted following European Medicines Agency (EMA) approval. It has been available in the US since September 2012.
It is manufactured by Meda Pharmaceuticals.